The Future of Biosimilars - A Case of Untapped Potential?
The patents on a majority of the top-selling biologic drugs currently on the market will have expired by 2020, an amount which may be equivalent to $67 billion. Can we expect then a rush of biosimilar products to the market, drastically lowering spend on biological drugs? If current trends are anything to go by, the answer is maybe not.
Biological drugs have boomed in the past decades and now they make up an impressive number of the world’s top selling drugs. According to Thompson Reut...
To continue reading this story get free access
Please note: That all fields marked with an asterisk (*) are required.